XML 47 R33.htm IDEA: XBRL DOCUMENT v3.21.2
Subsequent Events - Additional Information (Details)
$ / shares in Units, $ in Billions
 9 Months Ended 12 Months Ended
Oct. 13, 2021
USD ($)
Days
$ / shares
shares
Sep. 30, 2021
shares
Sep. 30, 2020
shares
Dec. 31, 2019
shares
Subsequent Event [Line Items]        
Consecutive Trading days | Days 90      
2021 LTPIP        
Subsequent Event [Line Items]        
Performance expiration date   Aug. 11, 2028    
Performance-based Stock Options        
Subsequent Event [Line Items]        
Granted   669,581 0 170,150
Subsequent Event        
Subsequent Event [Line Items]        
Plan description Up to 35% of the options may be earned through the attainment of certain operational milestones to the extent that number of options has not yet been earned from stock appreciation. A participant may earn up to 25% upon approval by the U.S. Food and Drug Administration of a Biologics License Application for KSI-301 in the three major anti-VEGF indications and up to 10% from generating sales of at least $2.5 billion in a fiscal year.      
Subsequent Event | 2021 LTPIP        
Subsequent Event [Line Items]        
Sales | $ $ 2.5      
Performance Periods 7 years      
Common stock, shares reserved for issuance 5,502,334      
Subsequent Event | 2021 LTPIP | Maximum        
Subsequent Event [Line Items]        
Stock Price | $ / shares $ 800      
Subsequent Event | 2021 LTPIP | Minimum        
Subsequent Event [Line Items]        
Stock Price | $ / shares $ 200      
Subsequent Event | 2018 Equity Incentive Plan | Performance-based Stock Options        
Subsequent Event [Line Items]        
Granted 1,920,625